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Abstract
Introduction: Chronic obstructive pulmonary disease (COPD) is a complex inflammatory condition that can affect haemostasis. This study aimed to 
determine differences in platelet-related parameters between controls and COPD subjects. The hypothesis was that platelet indices are disturbed in 
COPD patients, and this would be accompanied by increased C-reactive protein (CRP), fibrinogen (Fbg) and white blood cells (WBC). Therefore, plate-
let count (Plt), platelet-related parameters – mean platelet volume (MPV), platelet distribution width (PDW), plateletcrit (Pct), their ratios (MPV/Plt, 
MPV/Pct, PDW/Plt, PDW/Pct), platelet to lymphocyte ratio (PLR), Plt index as well as CRP, Fbg and WBC were assessed.
Materials and methods: Study included 109 patients with stable COPD and 95 control subjects, recruited at Clinical Department for Lung Diseases 
Jordanovac, University Hospital Centre Zagreb (Zagreb, Croatia). Complete blood count was performed on Sysmex XN-1000, CRP on Cobas c501, and 
Fbg on BCS XP analyser. Data were analysed with MedCalc statistical software.
Results: Platelet (P = 0.007) and PLR (P = 0.006) were increased, while other platelet indices were decreased in COPD patients compared to con-
trols. Combined model that included PLR, PDW and WBC showed great diagnostic performances, and correctly classified 75% of cases with an AUC 
of 0.845 (0.788 – 0.892), P < 0.001. Comorbidities (cardiovascular or metabolic diseases) had no effect on investigated parameters, while inhaled 
corticosteroids/long-acting β2-agonists (ICS/LABA) therapy increased MPV and PDW values in COPD patients.
Conclusion: Platelet indices were altered in COPD patients and they could be valuable as diagnostic markers of COPD development, especially if 
combined with already known inflammatory markers.
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Chronic obstructive pulmonary disease (COPD) is a 
complex and heterogeneous disease, additionally 
complicated by the presence of comorbidities, 
and is therefore often misdiagnosed and underes-
timated. However, in spite of that, it is projected to 
become the third leading cause of death by 2020. 
More than three million people worldwide die an-
nually of COPD, making this disease an important 
public health problem. Cigarette smoking is con-
sidered the main COPD etiological factor. Still, only 
15-20% smokers have COPD, and some other ge-
netic (mostly yet unidentified, except for a1-antit-
rypsin deficiency) and non-genetic (air pollution 
and biomass fuel exposure, among others) factors 
also contribute significantly to COPD development 
(1). Main characteristic of the disease is chronic and 
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irreversible airflow obstruction (2). Underlying 
mechanisms of COPD encompass protease-anti-
protease imbalance, oxidative stress and chronic 
inflammation. It was shown that consequences of 
COPD are not present only locally (in pulmonary 
compartment), and systemic manifestations are 
present in most of COPD patients as well. Consid-
ering all of the abovementioned facts, some COPD 
endotypes and phenotypes have been proposed, 
yet many has to be discovered. According to preci-
sion medicine, patients within a certain subgroup 
should have a specific diagnostic and therapeutic 
approach (3). Today, therapeutic treatments are 
guided by the Global Initiative for Chronic Ob-
structive Lung Disease (GOLD) recommendations, 
and include short-acting β2-agonists (SABAs) or 
short-acting muscarinic antagonists (SAMAs) that 
improve forced expiratory volume in one second 
(FEV1) and COPD symptoms, long-acting β2-
agonists (LABAs) and long-acting muscarinic an-
tagonists (LAMAs) that improve lung function, or 
inhaled corticosteroids (ICS) that are often com-
bined with long-acting bronchodilators (1). 
It has been shown that FEV1 is poorly associated 
with the symptoms, health status, exercise capaci-
ty and other relevant characteristics of COPD (4). 
Therefore, various parameters that are increased 
or decreased in the circulation due to the disease 
could be important in understanding of its devel-
opment and progression, response to therapy and 
effects of comorbidities (5). Systemic inflammation 
is recognized as a risk factor for many comorbidi-
ties in patients with COPD, which puts them at a 
greater risk of hospitalization and mortality (6). An 
increase in white blood cells (WBC) and a decrease 
in lymphocyte count was reported in COPD pa-
tients compared to healthy subjects as well as an 
increase in C-reactive protein (CRP), fibrinogen 
(Fbg), and inflammatory cytokines’ concentration 
(4,6–8). Inflammation was associated with the 
changes in structure, shape and dynamics of plate-
lets (9). Platelet indices that describe mentioned 
changes are platelet count (Plt), mean platelet vol-
ume (MPV), platelet distribution width (PDW) and 
plateletcrit (Pct). Platelets recruit leukocytes to the 
site of inflammation and begin many intercellular 
and intracellular processes that may further take 
part in atherogenic and thrombotic events (6,10). 
Mean platelet volume and PDW are considered 
the markers for platelet activation that are com-
monly increased in patients with thrombotic and 
atherogenic risk (6,11). However, in COPD patients, 
beside an increase, a decrease in MPV was also re-
ported due to the burden of inflammation pre-
sentable as exacerbation, intensive degradation of 
platelets or utilization of larger platelets at site of 
inflammation during the intercellular reactions 
(7,10,12,13). Platelet distribution width gives infor-
mation about diversity of platelet size, so there is 
an increase in PDW in case of platelet hyperpro-
duction, which cause the release of immature larg-
er platelets from bone marrow (14). Plateletcrit is a 
parameter that describes the blood volume occu-
pied by platelets. Regarding the definition of Pct 
and its formula, Pct = Plt x MPV / 10,000, it might 
be a kind of mechanism to maintain haemostasis 
by keeping the platelet mass unchanged (13). It 
was associated with various cardiovascular events, 
but also with COPD (6).
There is a need for information about changes in 
platelet indices in COPD patients. They are easily 
available in a daily laboratory routine, and if put in 
corresponding combinations they might achieve 
better predictive or diagnostic values. Thrombo-
cytosis is often followed by lymphopenia, so if the 
counts of platelets and lymphocytes are calculat-
ed in platelet to lymphocyte ratio (PLR), it could 
become more reliable in describing the inflamma-
tion status. Indeed, PLR showed a very good per-
formance as a potential inflammatory marker in 
various inflammatory diseases, including COPD 
(6,15). In addition, MPV/Plt ratio had a greater diag-
nostic value than MPV alone in pulmonary embo-
lism, and it was a promising prognostic marker for 
lethal outcome in severe sepsis (16,17).
This study aimed to determine differences in 
platelet-related and common inflammatory pa-
rameters (CRP, Fbg, WBC) between control group 
and patients with stable COPD, according to the 
GOLD stages and ABCD clinical assessment. The 
hypothesis was that platelet indices are disturbed 
in COPD patients, and this would be accompanied 
by increased CRP, Fbg and WBC. Thus, in addition 
to CRP, Fbg and WBC, platelets as well as platelet-
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related parameters (MPV, PDW, Pct), and ratios 
(MPV/Plt, PDW/Plt, MPV/Pct and PDW/Pct) were in-
vestigated. Only PLR was explored in COPD so far. 
In addition, Plt index that unites Plt, Pct, MPV and 
PDW in one parameter was used, with a formula 
Plt index = MPV x PDW / Plt x Pct (18). Moreover, 
prognostic value of platelet indices was investigat-
ed. Finally, influence of several general comorbidi-
ties and commonly used inhalation therapies on 
platelet-related parameters was assessed, as data 
on these important topics are scarce.
Materials and methods
Subjects
Present study was retrospective and included a to-
tal of 204 individuals - 109 in a stable phase of 
COPD and 95 in control group. The study was ap-
proved by Ethical Committee of University Hospi-
tal Centre Zagreb (Zagreb, Croatia) and by Ethical 
Committee for Experimentation of Faculty of Phar-
macy and Biochemistry, University of Zagreb (Za-
greb, Croatia). All participants signed an informed 
consent for scientific research and agreed to take 
part in it as volunteers. It does not imply consent 
to publish personal individual data (names, pic-
tures, hospital identification).
Patients with COPD were screened for eligibility 
and recruited during ambulatory visits at Clinical 
Department for Lung Diseases Jordanovac, Uni-
versity Hospital Centre Zagreb, during 2017 and 
2018. Consecutive patients, mostly current or for-
mer smokers of tobacco, aged 65 (45–87) years, 
with objectively confirmed COPD according to the 
GOLD guidelines were included. Chronic obstruc-
tive pulmonary disease was diagnosed by a spe-
cialist pulmonologist based on anamnesis and 
clinical review, current symptoms and spirometry 
measurements. According to the GOLD criteria, 
COPD patients had FEV1/ forced vital capacity 
(FVC) value < 0.70, and they were subdivided into 
the groups based on airflow limitation grade 
(GOLD 1-4 stages) (1). Patients with FEV1 ≥ 80%, 
were in GOLD 1, with 50% ≤ FEV1< 80% were in 
GOLD 2, 30% ≤ FEV1 < 50% is a criterion for GOLD 
3, and FEV1 < 30% for GOLD 4. Additionally, COPD 
patients were subdivided based on ABCD assess-
ment using COPD Assessment Test (CAT) question-
naire (GOLD A-D groups) (Figure 1). All COPD pa-
tients included in the study had to be in stable 
phase of the disease, which was defined as no ex-
acerbations during at least three visits in the previ-
ous 4 months, with no changes in respiratory 
medication and no symptoms of a lower respira-
tory tract infection. Apart from recent exacerba-
tions and lung function parameters, other exclu-
Figure 1. Subdivision of 109 COPD patients according to the severity of airflow limitation (GOLD 1-4 stages) and ABCD assessment 

















GOLD 1-4 stages GOLD A-D groups
A total of 109 COPD patients divided into the groups according to
the GOLD severty staging and GOLD ABCD clinical assessment
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sion criteria for COPD patients were: age under 40, 
lung diseases other than COPD, inflammatory sys-
temic diseases, acute infections, diabetes with se-
vere complications, severe liver diseases, severe 
kidney insufficiency, malignant diseases, trans-
plantations, and other specific or non-specific 
acute inflammations.
The control group was consisted of smokers and 
non-smokers, and their health state was estab-
lished based on anamnestic data and spirometry 
test results. Control individuals had to meet the 
same inclusion and exclusion criteria as the COPD 
patients, except for the findings of post-broncho-




Determination of platelet indices as well as some 
general inflammatory biomarkers was evaluated 
in the blood samples, obtained by venepuncture 
of a large antecubital vein, of patients with stable 
COPD and controls.
All participants (patients and controls) were told in 
advance not to eat for (at least) 8 hours before the 
blood collection that was performed between 7 
and 9 a.m. Fasting state was self-reported, and 
checked by nurse before blood collection.
For each individual, three blood tubes were drawn: 
for complete blood count (CBC) measurement – 
tube with K3EDTA anticoagulant for whole blood 
analysis (Greiner Bio-One, GmbH, Kremsmünster, 
Austria; volume 3 ml), for fibrinogen measurement 
– tube with 3.2% sodium citrate for plasma analy-
sis (Becton, Dickinson and Company, Franklin 
Lakes, NJ, USA; volume 4.5 ml), and for CRP meas-
urement – tube with gel without additive for se-
rum analysis (Greiner Bio-One, GmbH, Kremsmün-
ster, Austria; volume 5 ml). First, the blood was ex-
tracted into a coagulation tube with sodium cit-
rate and mixed by an inversion of 3-4 times, then 
into a biochemical tube with gel and finally into a 
hematologic tube with K3EDTA (both tubes were 
mixed with an inversion of 8 times). For venepunc-
ture and order of blood sampling and mixing, the 
guidelines were followed according to the nation-
al recommendations for venous blood sampling 
(19).
Complete blood count analysis was performed 
within half an hour after blood collection. Serum 
tube with gel was centrifuged at 2000xg for 10 
min, as recommended by the manufacturer, and 
coagulation tube with sodium citrate was centri-
fuged two times at 1500xg for 15 min, as recom-
mended by the Clinical and Laboratory Standards 
Institute (CLSI) guidelines, and by the manufactur-
er (20-22). Immediately thereafter, CRP and Fbg 
were measured.
Leukocyte, lymphocyte and Plt counts, as a part of 
CBC, were performed on Sysmex XN-1000 analyser 
(Sysmex Corporation, Kobe, Japan). Determination 
of leukocyte count and proportion of lympho-
cytes is based on the flow cytometry method 
where laser light scattering technology is used. 
Platelet counts and their respective indices are 
performed using the impedance method with hy-
drodynamic focusing. A platelet volume distribu-
tion curve is produced utilizing two thresholds: 
the lower move from 2 to 6 fL and the upper from 
12 to 30 fL. The MPV was obtained by dividing Pct 
by Plt number. Platelet distribution width, a meas-
ure of platelet anisocytosis, is the width (measured 
as fL) of the size distribution curve at 20% of the 
peak. Immunoturbidimetry was a method used for 
the CRP determination on Cobas c501 analyser 
(Roche Diagnostics GmbH, Mannheim, Germany). 
The measurement of Fbg was performed on BCS 
XP analyser (Siemens Healthcare Diagnostics, Mar-
burg, Germany). 
Internal quality control and external quality as-
sessment were performed for all parameters dur-
ing the study period, according to HRN EN ISO 
15189:2012 Medical laboratories - Requirements 
for quality and competence. The analysers were 
calibrated according to the manufacturer’s instruc-
tions and checked by using commercial controls. 
For CRP measurements commercial controls were 
used two times a day (PreciControl ClinChem Multi 
1 (PCCC1; cat. no: 511 700 3190) and PreciControl 
ClinChem Multi 2 (PCCC2; cat. no: 511 721 6190), 
Roche Diagnostics GmbH, Mannheim, Germany) 
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as well as for fibrinogen measurements (Control 
plasma N (cat. no: 05-ORKE41) and Control plasma 
P (cat. no: OUPZ175), Siemens Healthcare Diagnos-
tics, Marburg, Germany). For CBC measurements 
commercial control (Sysmex XN Check Level 1 (cat. 
no: 213 487), Level 2 (cat. no: 213 488), Level 3 (cat. 
no: 213 489), Sysmex Corporation, Kobe, Japan) 
was used once a day.
Spirometry
Spirometry is a common method in diagnosing 
the airflow limitation. It enables to measure FVC, 
that is a volume of vigorously exhaled air from the 
point of maximal inspiration, and FEV1, the other 
important parameter that stands for the volume of 
air exhaled during the first second of previously 
described procedure for measuring FVC. After-
wards, FEV1/FVC is calculated. If its value is < 0.70, 
the airflow limitation is confirmed. 
The spirometry was performed on each visit of 
COPD patients in outpatient clinic by trained tech-
nicians.  The spirometry was done on a Master-
Screen Pneumo (Jaeger, Germany), according to 
the recommendations of the European Respirato-
ry Society and American Thoracic Society.
Comorbidities and therapy
Study participants provided a detailed medical 
history that included comorbidities and therapy 
data. Both COPD patients and controls were subdi-
vided according to the presence of cardiovascular 
diseases (CVD) and metabolic diseases (MD). In this 
study, term CVD encompassed arterial hyperten-
sion, atherosclerosis, coronary artery disease and 
heart failure, while term MD encompassed diabe-
tes mellitus, osteoporosis and hyperlipidaemia.
Furthermore, COPD patients were also assigned to 
the groups according to the therapy so that the ef-
fect of various therapies on platelets and platelet-
related parameters could be determined. The pa-
tients were divided into four therapy groups, ac-
cording to the GOLD guidelines based on medical 
data. Therapy 1 group was taking SABA, SAMA, 
LAMA or LABA and every possible dual combina-
tion among them. Long-acting β2-agonists and 
LAMA as a constant combination were used in 
therapy 2 group, while therapy 3 group was taking 
ICS/LABA combination. Finally, addition of LAMA 
to ICS/LABA combination was taken by the indi-
viduals in therapy 4 group.
Statistical analysis
All data were tested for normal distribution by Kol-
mogorov-Smirnov test. As all data showed to be 
non-parametric, they were presented as median 
with interquartile range, and only age was pre-
sented as median with minimum and maximum. 
Accordingly, correlations were evaluated by Spear-
man Rank Order. Differences between controls 
and COPD groups were tested by Mann-Whitney 
Rank Sum Test, while in case of more than two 
groups Kruskal-Wallis One Way Analysis of Vari-
ance on Rank was used. Univariate and multivari-
ate logistic regression analysis were performed for 
evaluation of predicting factors in COPD. Data 
were considered statistically significant when P < 
0.05. Statistical analysis was performed by Med-
Calc statistical software, version 17.9.2. (MedCalc 
Software, Ostend, Belgium).
Results
Table 1 shows baseline characteristics of all partici-
pants included (age, sex, smoking status, spiro-
metric data) as well as results of laboratory testing. 
Controls and patients groups did not differ accord-
ing to age (64 (46-83) and 65 (45-87), respectively) 
and sex (49 male and 46 female vs. 69 male and 40 
female, respectively). All lung function parameters 
were significantly lower in subjects with COPD, as 
expected. Well-known inflammatory parameters, 
CRP, Fbg and WBC, showed increased levels in 
COPD patients compared to controls (P < 0.001 for 
all three parameters). An increase in Plt (P = 0.007), 
and a decrease in MPV (P < 0.001) and PDW (P < 
0.001) compared to control subjects were found. 
Among the other platelet-related parameters, Pct 
for itself did not show significant change between 
COPD patients and controls (P = 0.220), but when 
combined with MPV or PDW in a MPV/Pct or PDW/
Pct, lower result in COPD patients were obtained 
(P = 0.005 and P < 0.001, respectively). The same 
principle of calculation was used on Plt, so the 
MPV/Plt and PDW/Plt ratios were better in distin-
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Table 1. Baseline characteristics, spirometric, inflammatory and platelet-related parameters of controls and patients with stable COPD
Parameter ControlsN = 95
COPD





males; N/total 49/95 69/109
0.121
females; N/total 46/95 40/109
smoking status
current smokers, N (%) 47 (49%) 29 (27%)
former smokers, N (%) 0 (0%) 75 (69%) < 0.001


























































Plt index 259 (189-341)
190 
(147-251) < 0.001
Smoking status is presented as absolute numbers (percentages), and all other data are presented as the median (interquartile 
range), except for age that is presented as median (minimum – maximum); data were analysed by Mann-Whitney Rank Sum test.
COPD – chronic obstructive pulmonary disease. FEV1 - forced expiratory volume in 1 second. FVC - forced vital capacity. CRP - 
C-reactive protein. Fbg – fibrinogen. WBC - white blood cells. Plt - platelet count. PLR - platelet to lymphocyte ratio. MPV - mean 
platelet volume. PDW - platelet distribution width. Pct - plateletcrit.
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Figure 2. Values of Plt (A), PLR (B), MPV/Plt (C) and MPV/Pct (D) in control group and COPD groups subdivided by the severity of air-
flow limitation (GOLD 2-4 stages) and ABCD assessment (GOLD A-D groups). Results are shown as the median (interquartile range). 
GOLD 2-4 stages and GOLD A-D groups, compared to total number of controls included in the study, were tested by Kruskal-Wallis One 
Way Analysis of Variance on Ranks. Connectors on the graphs show between which groups was observed statistically significant differ-
ence with P < 0.05. GOLD - Global Initiative for Chronic Obstructive Lung Disease. Plt - platelet count. PLR - platelet to lymphocyte ratio. 
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guishing COPD patients and controls (P < 0.001, P 
< 0.001, respectively) than Plt itself. Platelet index 
was decreased in COPD patients when compared 
to control subjects (P < 0.001).
Platelet to lymphocyte ratio was significantly ele-
vated in COPD patients (P = 0.006). Moreover, PLR 
showed to be related to the disease severity, as a 
statistically significant differences were found be-
tween controls and GOLD 4 (P < 0.05) as well as 
between controls and GOLD D (P < 0.05). Platelet 
to lymphocyte ratio was not the only parameter 
that showed the change among GOLD 2-4 stages 
and GOLD A-D subgroups. Platelets also showed 
changes when patients were subdivided into 
GOLD 2-4 stages, but there was no significant 
change between GOLD A-D groups when com-
pared to controls and between individual groups. 
MPV/Plt and MPV/Pct ratios showed a downtrend 
with statistical significance between different 
groups, as shown in Figure 2. 
Fibrinogen demonstrated a poor positive correla-
tion with Plt (r = 0.40, P < 0.001) and Pct (r = 0.43, P 
< 0.001) in COPD patients. Negative correlation 
was observed with MPV/Plt (r = - 0.32, P < 0.001), 
MPV/Pct (r = - 0.40, P < 0.001), PDW/Plt (r = - 0.35, P 
< 0.001), PDW/Pct (r = - 0.29, P = 0.002) and Plt in-
dex (r = - 0.35, P < 0.001). Among all of the men-
tioned platelet-related parameters in control 
group, Fbg showed a negative correlation with 
PLR only (r = - 0.37, P < 0.001). In addition, univari-
ate logistic regression analysis (Table 2) showed 
that Fbg has the highest odds ratio value of all in-
dividual parameters tested (OR = 2.55 (95% CI = 
1.65-3.95), P < 0.001). Next, for multivariate logistic 
regression analysis all the parameters that showed 
statistically significant results in univariate logistic 
regression were included. As it is shown in Table 3. 
WBC, PDW and PLR gave the best combination for 
COPD prediction with its area under the curve 
(AUC) of 0.845 (95% CI = 0.788–0.892, P < 0.001) 
and 75% correctly classified cases.
Furthermore, controls and patients were subdivid-
ed into the groups depending on the presence of 
observed comorbidities (CVD or MD), and informa-
tion about the levels of platelets and their indices 
was provided. There were no statistically signifi-
cant changes between COPD patients with comor-
Parameter Odds ratio 95% CI P-value Correctly classified cases (%)
CRP 1.24 1.09-1.41 < 0.001 58.8
Fbg 2.55 1.65-3.95 < 0.001 60.8
WBC 1.48 1.25-1.76 < 0.001 51.0
Plt 1.01 1.00-1.01 0.015 61.8
PLR 1.01 1.00-1.02 0.004 54.4
MPV 0.59 0.43-0.80 < 0.001 62.8
PDW 0.72 0.62-0.84 < 0.001 63.7
PDW/Pct 1.00 1.00-1.00 0.003 62.7
CI – confidence interval. CRP - C-reactive protein. Fbg – fibrinogen. WBC - white blood cells. Plt – platelet. PLR - platelet to 
lymphocyte ratio. MPV - mean platelet volume. PDW - platelet distribution width. Pct - plateletcrit.
Table 2. Univariate logistic regression analysis with given predictors and protectors for COPD
parameter odds ratio 95% CI P-value
PLR 1.02 1.01-1.03 < 0.001
PDW  0.55 0.42-0.72 < 0.001
WBC 1.89 1.43-2.51 < 0.001
The analysis gave results with 75% correctly classified cases 
and area under curve of 0.845 (0.788–0.892). Only statistically 
significant results are shown in the table. CI – confidence 
interval. PLR - platelet to lymphocyte ratio. PDW - platelet 
distribution width. WBC - white blood cells.
Table 3. Multivariate logistic regression analysis of parameters 
whose results were statistically significant in univariate logistic 
regression analysis
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Parameter Comorbidity Controls 1 Controls 2 COPD 1 COPD 2 P-value













































 (9.6-10.7) < 0.001
a,b,d














 (10.4-13.0) < 0.001
a,b,c,d













(0.0021 - 0.0028) 0.476
















Results are presented as the median (interquartile range). Controls and chronic obstructive pulmonary disease (COPD) patients 
were subdivided based on the presence of comorbidity and they were tested by Kruskal-Wallis One Way Analysis of Variance on 
Ranks. controls 1 - controls with comorbidity. controls 2 - controls without comorbidity. COPD 1 - COPD patients with comorbidity. 
COPD 2 - COPD patients without comorbidity. CVD - cardiovascular diseases. MD - metabolic disorders. Plt - platelet count. PLR - 
platelet to lymphocyte ratio. MPV - mean platelet volume. PDW - platelet distribution width. Pct - plateletcrit.
CVD - controls 1, N = 24. controls 2, N = 71. COPD 1, N = 56. COPD 2, N = 53.
MD - controls 1, N = 25. controls 2, N = 70. COPD 1, N = 39. COPD 2, N = 70.
astatistically significant difference between controls 1 and COPD 1.
bstatistically significant difference between controls 2 and COPD 1.
cstatistically significant difference between controls 1 and COPD 2.
dstatistically significant difference between controls 2 and COPD 2.
Table 4. Effect of various comorbidities on platelets and platelet-related parameters
bidity and COPD patients without comorbidity. In 
cases of statistically relevant results, they were ob-
served between control groups when compared 
to COPD groups with or without comorbidity (Ta-
ble 4). 
Based on commonly used therapy - inhaled bron-
chodilators, either individually or in a combina-
tion, and ICS, COPD patients were subdivided into 
the groups according to if they were taking a spe-
cific therapy or not. The results regarding the influ-
ence of a specific therapy on platelets and plate-
let-related parameters are shown in Table 5. There 
were two statistically significant results, the level 
of MPV and the level of PDW were increased in 
COPD patients with therapy 3 (combination of 
LABA and ICS) when compared to COPD patients 
without therapy 3 (P = 0.038 and P = 0.026, respec-
tively). 
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therapy 1 122 (110-143)
136  
(101-171) 0.496
PLR therapy 2 130 (103-154)
139 
(101-169) 0.387
therapy 3 138 (102-173)
133  
(102-161) 0.764
therapy 4 150 (96-173)
130 
(103-151) 0.282
therapy 1 9.8 (9.5-10.2)
10.0 
(9.5-10.8) 0.294
MPV (fL) therapy 2 9.9 (9.5-10.8)
10.0  
(9.5-10.6) 0.894
therapy 3 10.4 (10.0-11.2)
9.9 
(9.4-10.5) 0.038
therapy 4 10.0 (9.2-10.6)
9.9  
(9.6-10.7) 0.456
therapy 1 10.6 (10.3-11.7)
11.4 
(10.2-12.9) 0.415
PDW (%) therapy 2 11.2 (10.2-12.5)
11.1 
(10.3-12.8) 0.910
therapy 3 12.3 (11.1-14.0)
11.1  
(10.1-12.3) 0.026
therapy 4 11.3  (9.6-12.6)
11.1  
(10.3-12.8) 0.387
therapy 1 0.002 (0.002-0.003)
0.002 
(0.002-0.003) 0.775
Pct therapy 2 0.002 (0.002-0.003)
0.003 
(0.002-0.003) 0.342
therapy 3 0.003  (0.002-0.003)
0.002 
(0.002-0.003) 0.166
therapy 4 0.003 (0.002-0.003)
0.002  
(0.002-0.003) 0.850
therapy 1 182 (157-230)
193  
(145-255) 0.627
Plt index therapy 2 197 (157-266)
188 
(134-245) 0.376
therapy 3 218 (138-242)
188  
(147-255) 0.590
therapy 4 183 (134-260)
194 
(152-248) 0.595
Results are presented as the median (interquartile range). COPD patients were subdivided based on the chronic inhalation therapy 
1, 2, 3 or 4, and they were tested by Mann-Whitney test. therapy 1 - SABA or SAMA or LAMA or LABA. therapy 2 - LABA/LAMA. 
therapy 3 - ICS/LABA. therapy 4 - ICS/LABA+LAMA.
SABA - short-acting β2-agonist. SAMA - short-acting muscarinic antagonist. LABA - long-acting β2-agonist. LAMA - long-acting 
muscarinic antagonist. ICS - inhaled corticosteroids. therapy 1: with, N = 20; without, N = 89. therapy 2: with, N = 32; without, N = 
77. therapy 3: with, N = 16; without, N = 93. therapy 4: with, N = 37; without, N = 72. Plt - platelet count. PLR - platelet to lymphocyte 
ratio. MPV - mean platelet volume. PDW - platelet distribution width. Pct - plateletcrit.
Table 5. Effect of chronic inhalation therapy on platelets and platelet-related parameters
Hlapčić I. et al. Platelet indices in airway obstructive disease
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Discussion
Study demonstrated that platelet indices were dis-
turbed in COPD patients. Indeed, Plt and PLR were 
increased, while other platelet-related parameters 
were decreased in COPD patients group compared 
to control subjects. Combined model that includ-
ed PLR, PDW and WBC showed great diagnostic 
performances, and correctly classified 75% of cas-
es with an AUC of 0.845 (95% CI = 0.788–0.892). 
Chronic obstructive pulmonary disease patients 
with or without comorbidities (CVD or MD) had 
similar values for all investigated parameters, while 
ICS/LABA therapy increased MPV and PDW values 
in COPD patients.
Increased Plt in patients with stable COPD com-
pared to age- and sex-matched controls, observed 
in this study, can be explained with the fact that 
an underlying inflammation in COPD stimulates 
bone marrow to synthesize platelets (9). In case of 
reduced platelet production, the newly synthe-
sized platelets have larger volume and are more 
active, as a result of compensation (16,17,23). In-
creased MPV could be considered as a marker of 
platelet activation (6,11,14,16). However, there are 
some differences in results between the studies. In 
this study, MPV was decreased in patients with sta-
ble COPD in comparison to controls, which may 
suggest that platelets in the circulation are less ac-
tive and, therefore, patients with stable COPD are 
at lower risk for thrombotic events. Some studies 
suggested that a decrease in MPV levels could be a 
consequence of involvement and utilization of 
larger platelets at site of inflammation. Therefore, 
smaller platelets remain and cause a reduction in 
MPV levels (24,25). Chronic obstructive pulmonary 
disease patients had lower MPV during an exacer-
bation episode, and the level increased after the 
recovery period (12). Accordingly, following up the 
MPV levels could be used for monitoring the re-
covery after the exacerbation (7). Beside a lower 
MPV in acute exacerbation, a decrease in MPV was 
also found before in stable phase of COPD when 
compared to control group (12). Therefore, it 
would be valuable to assess MPV in larger groups 
of controls and stable COPD patients as well as in 
COPD patients with exacerbations to clarify more 
controversial results obtained in some publica-
tions.
Mean platelet volume levels could differ in the 
studies as the consequence of preanalytical fac-
tors as much as the analysis itself (25). Indeed, fac-
tors such as age, gender, race, ethnicity, lifestyle 
and genetic background, the venepuncture meth-
od, the anticoagulant used, type or sample, and 
many more, as much as the analysis itself regard-
ing a diversity of methods, could have an effect on 
MPV values (25). Moreover, inter-individual differ-
ences in response to the changes in the diseases 
should be considered as a factor that affects not 
only MPV (9,11). Besides MPV, the other marker 
used for detection of platelet activation is PDW, a 
parameter that describes platelet volume hetero-
geneity (14). Similar to MPV, PDW was also de-
creased in this study, which potentiated the sug-
gestion on lower platelets’ activity in patients with 
stable COPD. Both MPV and PDW showed odds ra-
tios lower than one in univariate logistic regres-
sion analysis (0.59 and 0.72, respectively), which 
means that they showed a protective role. Moreo-
ver, when combined with PLR and WBC in a multi-
variate logistic regression analysis, PDW showed 
even lower odds ratio of 0.55.
Some studies applied combinations of MPV and 
PDW with Plt and Pct (MPV/Plt, MPV/Pct, PDW/Plt, 
PDW/Pct, Plt index) when investigating different 
diseases and conditions, in an attempt to increase 
diagnostic performances of the ratios compared 
to individual parameters (2,6,18,26). Only PLR was 
investigated in COPD so far (2,6,15). In this study, 
from all individual parameters examined, only Plt 
distinguished COPD patients from controls regard-
ing criteria for GOLD 2-4 stages, but not for GOLD 
A-D groups. However, even three different plate-
let-related ratios could provide distinction in com-
parison of either GOLD 2-4 stages or GOLD A-D 
groups with control subjects, namely MPV/Plt, 
MPV/Pct and PLR.
This investigation showed that PLR is increased in 
stable COPD, with statistically different results be-
ing observed between control group and GOLD 4 
as well as between control group and GOLD D. 
Platelet to lymphocyte ratio can be used as a diag-
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nostic indicator of systemic inflammation. It is bet-
ter parameter than Plt and lymphocyte count indi-
vidually because it associates their general inverse 
relation and reduces the impact of preanalytical 
factors, such as blood specimen handling and lev-
el of hydration, on individual parameters (6,27). 
Moreover, when PLR, PDW and WBC were com-
bined, this three-component model showed a 
very good diagnostic prediction for the presence 
of COPD (75% of cases could be correctly classi-
fied). Diagnostic performances of this combina-
tion exceeded those of any individual platelet-re-
lated or common inflammatory parameters that 
were also explored in this study.
Patients with stable COPD had increased levels of 
inflammatory proteins (CRP and Fbg) and cells 
(WBC), which are non-invasive, easily measured, 
inexpensive parameters (28). Elevated Fbg was 
more than two times expected to be seen in pa-
tients with stable COPD than in controls (OR = 
2.55). According to that, Fbg seems to be a good 
COPD predictor; however, this interpretation 
should be taken with caution, as Fbg is a non-spe-
cific acute phase parameter. Moreover, Fbg posi-
tively (Plt, Pct) or negatively (MPV/Plt, MPV/Pct, 
PDW/Plt, PDW/Pct, Plt index) correlated with plate-
let indices in COPD patients.
It was shown that increased Fbg is associated with 
reduced lung function and increased risk of COPD 
(29). Many COPD patients have cardiovascular co-
morbidities, and Fbg is also associated with cardi-
ovascular mortality (28). However, in this study no 
significant differences in Fbg values were found 
between individuals (controls or COPD patients) 
with CVD and those without CVD (data not shown).
Regarding platelets and their related parameters, 
statistically relevant results were not observed ei-
ther between control individuals with and without 
comorbidities or between COPD patients with and 
without comorbidities (CVD or MD). Further stud-
ies with larger subgroups having those or some 
other common comorbidity are needed for results 
to be more significant.
In order to improve the quality of life (by affecting 
lung function and/or underlying inflammation), 
COPD patients are subjected to long-lasting thera-
py regimes that are adjusted to their current symp-
toms and overall state. Patients in this study re-
ceived four different chronic inhalation treat-
ments. Those therapy regimes affected MPV and 
PDW only; specifically, ICS/LABA combination in-
creased their values. Data of influence on COPD 
therapy on haematological or biochemical blood 
parameters are rarely found. It is necessary to do 
more research with the aim to determine if the 
reason for no changes is in inefficient therapy or 
platelet-related parameters do not have a poten-
tial in monitoring the therapy (30).
There are several shortcomings of this study. The 
sample size was relatively small, especially for sub-
groups with respect to the disease severity (either 
GOLD 2-4 stages or GOLD A-D groups), the pres-
ence of comorbidity and therapy. In addition, no 
patient with GOLD 1 stage participated in this 
study and it would be interesting to investigate 
the pattern of platelet indices at the beginning of 
the disease development; however, unfortunately, 
this group of COPD patients rarely contact their 
physician due to very mild symptoms. At the be-
ginning, patients were recruited according to the 
inclusion criteria and later on were subdivided ac-
cording to the GOLD category A-D. This is the rea-
son why no patient in the GOLD C category par-
ticipated in this study. However, these results are 
consistent with available data showing that GOLD 
C category of patients is very rare (patients that 
does not have many symptoms usually are not fre-
quent exacerbators).
It was observed that MPV and PDW have a poten-
tial of being protective parameters and that could 
be evaluated if a group of COPD patients with ex-
acerbations is included in the study. According to 
that, large-scale prospective study for evaluation 
and validation of the results from current study 
should be considered.
In conclusion, after determining potentially good 
COPD biomarkers, it is required to assess their re-
producibility for clinical practice. With a combina-
tion of several different biomarkers, better clinical 
protocol in COPD diagnostics, therapy monitoring 
and defining of new phenotypes and endotypes 
could be achieved. When combining PLR, PDW 
Hlapčić I. et al. Platelet indices in airway obstructive disease
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and WBC, 75% of cases were correctly classified in 
this study, and a very good diagnostic power be-
tween controls and COPD subjects was accom-
plished. Considering many existing changes in 
thrombotic events, platelets could become an at-
tractive diagnostic and therapeutic target. Anoth-
er important advantage is that platelets and their 
indices are common, inexpensive and non-inva-
sive tests performed routinely in everyday labora-
tory practice.
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